- » Aim and Scope
- » Section Policies
- » Publication Frequency
- » Author Self-Archiving
- » Archiving
- » Peer-Review
- » Publishing Ethics
- » Founder
- » Author fees
- » Disclosure and Conflict of Interest
- » Plagiarism detection
- » Preprint and postprint Policy
- » Policy on revocation or correction of articles
- » Personal data processing policy
- » Policy on the Use of Artificial Intelligence Services
- » Authorship Policy and Contribution Statement
- » Complaints and Appeals Policy
- » Conflict of Interest Policy
- » Policy on Data Sharing and Reproducibility
- » Policy on Biomedical Ethical Oversight
- » Policy for Post-Publication Discussions and Corrections
- » Policy upon detection of fraudulent publication
Aim and Scope
The aim of the journal: The main theme of the journal is focused on informing physicians, pharmacologists, biologists, chemists, healthcare providers, clinicians, pharmaceutical companies, and other professionals about new antibacterial, antifungal, antiviral, antitumor, immunocorrector, and non-steroidal anti-inflammatory drugs; about the mechanisms of antibiotic resistance of infectious agents, the effectiveness and tolerability of antibacterial drugs in experiments and in clinic; about modern express methods for identifying and determining the sensitivity of infectious pathogens; about principles of rational antibiotic therapy and antibiotic prophylaxis of the most common infectious and inflammatory diseases.
The objectives of the journal are:
Promoting the implementation of scientific and practical knowledge and methodological approaches in the field of search and creation of medicines, preclinical and clinical chemotherapy, as well as microbiology among doctors of various specialties.
Section Policies
Open Submissions
IndexedPublication Frequency
6 issues per year
Archiving
- Russian State Library (RSL)
- National Electronic-Information Consortium (NEICON)
Peer-Review
A bilateral anonymous ("blind") peer review method is mandatory for processing of all scientific manuscripts submitted to the editorial stuff of journal "Antibiotics and Chemotherapy". This implies that neither the reviewer is aware of the authorship of the manuscript, nor the author maintains any contact with the reviewer.
- Leading Russian experts in corresponding areas of life sciences, invited as independent readers, perform peer reviews. Editor-in-chief, deputy editor-in-chief or science editor choose readers for peer review. We aim to limit the review process to 8 weeks, though in some cases the schedule may be adjusted at the reviewer’s request.
- Reviewer has an option to abnegate the assessment should any conflict of interests arise that may affect perception or interpretation of the manuscript. Upon the scrutiny, the reviewer is expected to present the editorial board with one of the following recommendations:
- to accept the paper in its present state;
- to invited the author to revise their manuscript to address specific concerns before final decision is reached;
- that final decision be reached following further reviewing by another specialist;
- to reject the manuscript outright.
- If the reviewer has recommended any refinements, the editorial staff would suggest the author either to implement the corrections, or to dispute them reasonably. Authors are kindly required to limit their revision to 2 months and resubmit the adapted manuscript within this period for final evaluation.
- We politely request that the editor to be notified verbally or in writing should the author decide to refuse from publishing the manuscript. In case the author fails to do so within 3 months since receiving a copy of the initial review, the editorial board takes the manuscript off the register and notifies the author accordingly.
- If author and reviewers meet insoluble contradictions regarding revision of the manuscript, the editor-in-chief resolves the conflict by his own authority.
- The editorial board reaches final decision to reject a manuscript on the hearing according to reviewers’ recommendations, and duly notifies the authors of their decision via e-mail. The board does not accept previously rejected manuscripts for re-evaluation.
- Upon the decision to accept the manuscript for publishing, the editorial staff notifies the authors of the scheduled date of publication.
- Kindly note that positive review does not guarantee the acceptance, as final decision in all cases lies with the editorial board. By his authority, editor-in-chief rules final solution of every conflict.
- Original reviews of submitted manuscripts remain deposited for 5 years.
Publishing Ethics
The Publication Ethics and Publication Malpractice Statement of the journal "Antibiotics and Chemotherapy" are based on the Committee on Publication Ethics (COPE) Code of Conduct guidelines available at www.publicationethics.org and requirements for peer-reviewed medical journals (http://health.elsevier.ru/attachments/editor/file/ethical_code_final.pdf), elaborated by the Elsevier Publishing House (in accordance with international ethical rules of scientific publications)
1. Introduction
1.1. The publication in a peer reviewed learned journal, serves many purposes outside of simple communication. It is a building block in the development of a coherent and respected network of knowledge. For all these reasons and more it is important to lay down standards of expected ethical behavior by all parties involved in the act of publishing: the author, the journal editor, the peer reviewer, the publisher and the society for society-owned or sponsored journal: "Antibiotics and Chemotherapy".
1.2. Publisher has a supporting, investing and nurturing role in the scholarly communication process but is also ultimately responsible for ensuring that best practice is followed in its publications.
1.3. Publisher takes its duties of guardianship over the scholarly record extremely seriously. Our journal programs record «the minutes of science» and we recognize our responsibilities as the keeper of those «minutes» in all our policies not least the ethical guidelines that we have here adopted.
2. Duties of Editors
2.1. Publication decision – The Editor of the journal "Antibiotics and Chemotherapy" is solely and independently responsible for deciding which of the articles submitted to the journal should be published, often working on conjunction with the relevant society (for society-owned or sponsored journals). The validation of the work in question and its importance to researchers and readers must always underwrite such decisions. The Editor may be guided by the policies of the "Antibiotics and Chemotherapy" journal’s editorial board and constrained by such legal requirements as shall then be in force regarding libel, copyright infringement and plagiarism. The editor may confer with other editors or reviewers (or society officers) in making this decision.
2.2. Fair play – An editor should evaluate manuscripts for their intellectual content without regard to race, gender, sexual orientation, religious belief, ethnic origin, citizenship, or political philosophy of the authors.
2.3. Confidentiality – The editor and any editorial staff of "Antibiotics and Chemotherapy" must not disclose any information about a submitted manuscript to anyone other than the corresponding author, reviewers, potential reviewers, other editorial advisers, and the publisher, as appropriate.
2.4. Disclosure and Conflicts of interest
2.4.1. Unpublished materials disclosed in a submitted manuscript must not be used in an editor’s own research without the express written consent of the author. Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage.
2.4.2. Editors should recuse themselves (i.e. should ask a co-editor, associate editor or other member of the editorial board instead to review and consider) from considering manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or (possibly) institutions connected to the papers.
2.5. Vigilance over published record – An editor presented with convincing evidence that the substance or conclusions of a published paper are erroneous should coordinate with the publisher (and/or society) to promote the prompt publication of a correction, retraction, expression of concern, or other note, as may be relevant.
2.6.Involvement and cooperation in investigations – An editor should take reasonably responsive measures when ethical complaints have been presented concerning a submitted manuscript or published paper, in conjunction with the publisher (or society). Such measures will generally include contacting the author of the manuscript or paper and giving due consideration of the respective complaint or claims made, but may also include further communications to the relevant institutions and research bodies.
3. Duties of Reviewers
3.1. Contribution to Editorial Decisions – Peer review assists the editor in making editorial decisions and through the editorial communications with the author may also assist the author in improving the paper. Peer review is an essential component of formal scholarly communication, and lies at the heart of the scientific method. Publisher shares the view of many that all scholars who wish to contribute to publications have an obligation to do a fair share of reviewing.
3.2. Promptness – Any selected referee who feels unqualified to review the research reported in a manuscript or knows that its prompt review will be impossible should notify the editor of "Antibiotics and Chemotherapy" and excuse himself from the review process.
3.3. Confidentiality – Any manuscripts received for review must be treated as confidential documents. They must not be shown to or discussed with others except as authorized by the editor.
3.4. Standard and objectivity – Reviews should be conducted objectively. Personal criticism of the author is inappropriate. Referees should express their views clearly with supporting arguments.
3.5. Acknowledgement of Sources – Reviewers should identify relevant published work that has not been cited by the authors. Any statement that an observation, derivation, or argument had been previously reported should be accompanied by the relevant citation. A reviewer should also call to the editor’s attention any substantial similarity or overlap between the manuscript under consideration and any other published paper of which they have personal knowledge.
3.6. Disclosure and Conflict of Interest
3.6.1. Unpublished materials disclosed in a submitted manuscript must not be used in a reviewer’s own research without the express written consent of the author. Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage.
3.6.2. Reviewers should not consider manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or institutions connected to the papers.
4. Duties of Authors
4.1. Reporting standards
4.1.1. Authors of reports of original research should present an accurate account of the work performed as well as an objective discussion of its significance. Underlying data should be represented accurately in the paper. A paper should contain sufficient detail and references to permit others to replicate the work. Fraudulent or knowingly inaccurate statements constitute unethical behavior and are unacceptable.
4.1.2. Review and professional publication articles should also be accurate and objective, and editorial 'opinion’ works should be clearly identified as such.
4.2. Data Access and Retention – Authors may be asked to provide the raw data in connection with a paper for editorial review, and should be prepared to provide public access to such data (consistent with the ALPSP-STM Statement on Data and Databases), if practicable, and should in any event be prepared to retain such data for a reasonable time after publication.
4.3. Originality and Plagiarism
4.3.1. The authors should ensure that they have written entirely original works, and if the authors have used the work and/or words of others, this has been appropriately cited or quoted.
4.3.2. Plagiarism takes many forms, from ‘passing off’ another’s paper as the author’s own paper, to copying or paraphrasing substantial parts of another’s paper (without attribution), to claiming results from research conducted by others. Plagiarism in all its forms constitutes unethical publishing behavior and is unacceptable.
4.4. Multiple, Redundant or Concurrent Publication
4.4.1. An author should not in general publish manuscripts describing essentially the same research in more than one journal of primary publication. Submitting the same manuscript to more than one journal concurrently constitutes unethical publishing behavior and is unacceptable.
4.4.2. In general, an author should not submit for consideration in another journal a previously published paper.
4.4.3. Publication of some kinds of articles (eg, clinical guidelines, translations) in more than one journal is sometimes justifiable, provided certain conditions are met. The authors and editors of the journals concerned must agree to the secondary publication, which must reflect the same data and interpretation of the primary document. The primary reference must be cited in the secondary publication. Further detail on acceptable forms of secondary publication can be found at www.icmje.org.
4.5. Acknowledgement of Sources – Proper acknowledgment of the work of others must always be given. Authors should cite publications that have been influential in determining the nature of the reported work. Information obtained privately, as in conversation, correspondence, or discussion with third parties, must not be used or reported without explicit, written permission from the source. Information obtained in the course of confidential services, such as refereeing manuscripts or grant applications, must not be used without the explicit written permission of the author of the work involved in these services.
4.6. Authorship of the Paper
4.6.1. Authorship should be limited to those who have made a significant contribution to the conception, design, execution, or interpretation of the reported study. All those who have made significant contributions should be listed as co-authors. Where there are others who have participated in certain substantive aspects of the research project, they should be acknowledged or listed as contributors.
4.6.2. The corresponding author should ensure that all appropriate co-authors and no inappropriate co-authors are included on the paper, and that all co-authors have seen and approved the final version of the paper and have agreed to its submission for publication.
4.7. Hazards and Human or Animal Subjects
4.7.1. If the work involves chemicals, procedures or equipment that have any unusual hazards inherent in their use, the author must clearly identify these in the manuscript.
4.7.2. If the work involves the use of animal or human subjects, the author should ensure that the manuscript contains a statement that all procedures were performed in compliance with relevant laws and institutional guidelines and that the appropriate institutional committee(s) have approved them. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.
4.8. Disclosure and Conflicts of Interest
4.8.1. All authors should disclose in their manuscript any financial or other substantive conflict of interest that might be construed to influence the results or interpretation of their manuscript. All sources of financial support for the project should be disclosed.
4.8.2. Examples of potential conflicts of interest which should be disclosed include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Potential conflicts of interest should be disclosed at the earliest possible stage.
4.9. Fundamental errors in published works – When an author discovers a significant error or inaccuracy in a published work, it is the author’s obligation to promptly notify the editor of "Antibiotics and Chemotherapy" journal and cooperate with Publisher to retract or correct the paper, If the editor or the publisher learn from a third party that a published work contains a significant error, it is the obligation of the author to promptly retract or correct the paper.
5. Duties of the Publisher (and if relevant, Society)
5.1. Publisher should adopt policies and procedures that support editors, reviewers and authors of "Antibiotics and Chemotherapy" in performing their ethical duties under these ethics guidelines. The publisher should ensure that the potential for advertising or reprint revenue has no impact or influence on editorial decisions.
5.2. The publisher should support "Antibiotics and Chemotherapy" journal editors in the review of complaints raised concerning ethical issues and help communications with other journals and/or publishers where this is useful to editors.
5.3. Publisher should develop codes of practice and inculcate industry standards for best practice on ethical matters, errors and retractions.
5.4. Publisher should provide specialized legal review and counsel if necessary.
Founder
- Ministry of Health of the Russian Federation
- State Scientific Research Center of Antibiotics
Author fees
The editorial board of the journal "Antibiotics and Chemotherapy" is interested in publishing the results of your work.
Publication in the journal "Antibiotics and Chemotherapy" is free for authors.
The editorial board does not charge authors for preparing the material for publication (review, review, editing, proofreading, layout), posting on the journal's website https://www.antibiotics-chemotherapy.ru/jour, in eLibrary.ru, Cyberleninka and other indexed databases and depositories.
There is no fee for publishing manuscripts of applicants for the degree of candidate of sciences and doctor of sciences, while the articles should not be of an advertising nature and contain trade names of drugs and medical devices. In this case, it is necessary to attach a cover letter - Referral for publication from a research institution on the letterhead of the institution and with the signature of an official.
Publication fees are charged only in the following cases:
- If assistance is needed in technical preparation of the manuscript for review.
- If the authors wish to publish the article with pre-print publication with accelerated review ("Online First", Accepted for publication in electronic form).
- If the authors wish to publish the article urgently ("Fast Track").
Authors pay for editorial services themselves or at the expense of grants, affiliated organizations, etc.
The cost of services provided does not depend on the volume of work and the number of co-authors.
In case of a negative review of the article, payment is not refunded.
Payment for the publication of retracted articles is not refunded.
Paid services for authors:
- Technical preparation of the manuscript for review: bringing the submitted manuscript into compliance with the requirements of international rules for authors, which takes a lot of time and editorial resources. The procedure includes correcting technical errors in the submitted manuscript made by the author, including proper formatting of the bibliography, checking for ease of reading, compliance with the genre, use of abbreviations, etc.; proofreader, editor services; translation of the article title, abstract, figure and table titles into English.
Payment procedure: after receiving the manuscript, an initial assessment is made for compliance with the journal's subject matter. Manuscripts that do not correspond to the subject matter are rejected at this stage. If the manuscript is recognized as corresponding to the subject matter of the journal, a letter from the editors is sent to the e-mail address of the author responsible for correspondence with a request to make payment. In parallel, the Antiplagiat system is used to check. After receiving payment, the manuscript is reviewed by the editorial staff. They help the corresponding author with recommendations to technically prepare the manuscript for review, including the structure, design of illustrations and the list of references. After checking by the Antiplagiat system and technical revision, the manuscript undergoes review. After receiving a positive review, the manuscript will be published in order of priority. In case of a negative review, payment is not refunded.
The cost of the service is 15,000 (fifteen thousand) rubles per work.
- Pre-print publication of an article with accelerated peer review (Online First, Accepted for publication in electronic form). The article is posted on the journal's website with a DOI assigned, which makes it possible to reference and take the publication into account in the list of printed works; the article in printed form is published in any of the future issues in order of priority. Includes the following services:
- Technical preparation of the manuscript for review.
- Accelerated review.
- Publication in electronic form on the Internet on the journal's website in the "Accepted for publication" section ("Online First").
- Publication in printed form in any of the future issues of the journal in order of priority.
The cost of the service is 25,000 (twenty-five thousand) rubles per work.
- Urgent publication (Fast Track): the article approved by the reviewers and the editorial board is published in the next issue of the journal. Includes the following services:
- Technical preparation of the manuscript for review.
- Accelerated review.
- Publication in electronic form on the Internet on the journal's website in the "Accepted for publication" section ("Online First").
- Publication on a priority basis in the next issue of the journal being prepared ("Fast Track").
The cost of the service is 45,000 (fourty-five thousand) rubles per work.
__________
For all questions, please contact Elena Afanasyeva by phone: +7 (916) 986-04-65; e-mail: eva88@list.ru.
__________
General Director of LLC Publishing House OKI
Elena Afanasyeva
Phone: +7 (916) 986-04-65
Email: eva88@list.ru
The proposal is not a public offer.
06.01.2024, Moscow
Disclosure and Conflict of Interest
Unpublished materials disclosed in a submitted manuscript must not be used in a reviewer’s own research without the express written consent of the author. Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage.
Reviewers should not consider manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or institutions connected to the papers.
Plagiarism detection
“Antibiotics and Chemotherapy" use native russian-language plagiarism detection software Antiplagiat to screen the submissions. If plagiarism is identified, the COPE guidelines on plagiarism will be followed.
Preprint and postprint Policy
Prior to acceptance and publication in “Antibiotics and Chemotherapy", authors may make their submissions available as preprints on personal or public websites.
As part of submission process, authors are required to confirm that the submission has not been previously published, nor has been submitted. After a manuscript has been published in “Antibiotics and Chemotherapy" we suggest that the link to the article on journal's website is used when the article is shared on personal or public websites.
Glossary (by SHERPA)
Policy on revocation or correction of articles
Editors should consider retracting a publication if:
- They have clear evidence that the findings are unreliable, either as a result of major error (eg, miscalculation or experimental error), or as a result of fabrication (eg, of data) or falsification (eg, image manipulation)
- It constitutes plagiarism
- The findings have previously been published elsewhere without proper attribution to previous sources or disclosure to the editor, permission to republish, or justification (ie, cases of redundant publication)
- It contains material or data without authorisation for use
- Copyright has been infringed or there is some other serious legal issue (eg, libel, privacy)
- It reports unethical research
- It has been published solely on the basis of a compromised or manipulated peer review process
- The author(s) failed to disclose a major competing interest (a.k.a. conflict of interest) that, in the view of the editor, would have unduly affected interpretations of the work or recommendations by editors and peer reviewers.
Notices of retraction should:
- Be linked to the retracted article wherever possible (ie, in all online versions)
- Clearly identify the retracted article (eg, by including the title and authors in the retraction heading or citing the retracted article)
- Be clearly identified as a retraction (ie, distinct from other types of correction or comment)
- Be published promptly to minimise harmful effects
- Be freely available to all readers (ie, not behind access barriers or available only to subscribers)
- State who is retracting the article
- State the reason(s) for retraction
- Be objective, factual and avoid inflammatory language.
Retractions are not usually appropriate if:
- The authorship is disputed but there is no reason to doubt the validity of the findings
- The main findings of the work are still reliable and correction could sufficiently address errors or concerns
- An editor has inconclusive evidence to support retraction, or is awaiting additional information such as from an institutional investigation (for information about Expressions of Concern see https://publicationethics.org/expressions-of-concern-forum-discussion)
- Author conflicts of interest have been reported to the journal after publication, but in the editor’s view these are not likely to have influenced interpretations or recommendations or the conclusions of the article.
For more information: COPE (Version 2: November 2019)
https://publicationethics.org/files/retraction-guidelines.pdf
Personal data processing policy
Information about the authors (last name, first name, patronymic, name of the affiliated organization, e-mail address for readers to contact the author) provided by them for publication in the journal becomes available to an indefinite number of persons, to which the authors give written consent by the fact of the Offer concept when uploading the article to the online article acceptance system on the journal’s website. The publication of this information is carried out in the interests of the authors for the purpose of full and correct accounting of publications and their citation by the relevant bibliographic organizations and ensuring the possibility of contacts between authors and the scientific community.
Personal information provided by the authors to the journal in addition to the above information, including additional e-mail addresses and phone numbers, will be used exclusively for contacts with the authors during the preparation of the article for publication. The editorial board does not transfer this personal information to third parties who may use it for other purposes.
Policy on the Use of Artificial Intelligence Services
This Policy governs the use of artificial intelligence (hereinafter — AI) services by authors, reviewers, and editors at all stages of the publishing process: manuscript writing, peer review, and editorial preparation. The Journal recognizes that generative and other AI tools may serve as useful aids but cannot replace scientific expertise, critical thinking, or authorial responsibility. The purpose of this Policy is to uphold the principles of academic transparency and ethics in scientific publishing.
- Scope
This Policy applies to all articles except those directly devoted to artificial intelligence, where AI services are the subject of description or illustration of the manuscript’s content.
- General Principles
- AI is not and cannot be listed as a co‑author. AI tools (including language models, image generation systems, code generators, etc.) shall not be included in the author or co‑author byline.
- Authors shall not delegate to AI the authority to make scientifically significant decisions (such as hypothesis formation, result interpretation, conclusions, and recommendations) without their own critical oversight.
- Responsibility for the content of the manuscript—including text, data, figures, code, and references—always lies fully with the named authors. Authors are required to thoroughly verify and edit the manuscript prior to submission to the editorial office, including the bibliography and accuracy of citations.
- Disclosure of AI Use
Any substantial use of generative AI in the preparation of a manuscript must be explicitly disclosed in a separate section (e.g., “Section on disclosure of AI use”, within the “Acknowledgments” subsection, or “Statement on AI use”) with a brief description of:
- which specific tools were used (name, version/model, provider);
- at which stage and for what purpose (e.g., “language editing of the Discussion section”, “assistance in structuring the Introduction”).
Example wording: “In the preparation of this article, the following AI services were used: [name, version/model] for [purpose]. All outputs have been verified by the authors; no confidential or previously unpublished data were uploaded to public services.”
Grammar, spelling, and punctuation checks, as well as translation of manuscript excerpts into a foreign language, do not require disclosure.
Disclosure of AI use does not relieve authors of responsibility for the completeness, accuracy, and integrity of the data and conclusions presented.
- Permissible Use of AI
AI may be used as an auxiliary tool for:
- language editing and stylistic improvement of already written text;
- assistance in structuring material, formulating titles and abstracts;
- spell‑checking, grammar checking, and basic formatting;
- technical assistance in preparing cover letters.
In all cases, authors are required to carefully verify and, if necessary, correct the outputs of AI, avoiding factual errors, distortion of meaning, plagiarism, or incorrect references. Authors must retain a trace of use (prompts/scripts/parameters) and provide it to the editorial office upon request.
- Impermissible Use of AI
AI use is strictly prohibited for:
- generating, modifying, or “enhancing” research data, images, diagrams, or code that are presented as actual research results;
- fabricating, falsifying, or concealing data, as well as creating “mock” data instead of empirically obtained results;
- writing substantive sections of the manuscript without author involvement (generating text that is presented as entirely original scholarly contribution without substantial revision and verification by the authors);
- automatic selection, invention, or distortion of bibliographic references;
- preparing or substantively editing illustrative material (data visualizations), except for color correction that does not alter the content;
- circumventing peer review procedures, simulating reviews, or presenting others’ ideas as one’s own.
- Responsibilities of Reviewers and Editorial Board Members
Reviewers, editorial board members, and employees of OKI Publishing LLC may use AI tools only in exceptional cases as an auxiliary means for language editing of their own review text, subject to the following conditions:
- full preservation of confidentiality of the manuscript and review (strictly prohibited is uploading the manuscript, its fragments, illustrations, tables, unpublished data, or parts of the review to public AI services);
- complete personal control over the content, tone, and correctness of the review.
The use of AI to automatically generate reviews or decisions on a manuscript is not permitted. An exception is made for plagiarism detection systems operated under an agreement with aggregators that ensures the confidentiality of manuscript texts.
- Confidentiality, Data, and Copyright
When using AI, authors, reviewers, and editors are obliged to:
- not upload confidential or personal data to public AI services without a corresponding legal basis and consent (a public AI service means an external online platform where the provider may store or use the input data);
- respect copyright and third‑party rights, and not use AI to create derivative works that infringe intellectual property rights.
Authors are responsible for ensuring that all illustrations, tables, and other materials created with the involvement of AI do not violate third‑party rights and comply with the Journal’s requirements regarding ethics and copyright.
- Violations and Consequences
Violation of this Policy shall be treated as a potential breach of publication ethics (including data fabrication, plagiarism, concealment of information, or misleading the editorial office and readers). Depending on the severity of the violation, the Journal may take measures ranging from requesting clarifications and correcting the manuscript to rejection, retraction of a published article, and notification of the authors’ institutions or relevant ethics committees.
- Effective Date and Revision
This Policy is regularly reviewed and updated in light of the development of AI services and evolving standards of publication ethics.
Version 2, dated 28 April 2026.
Authorship Policy and Contribution Statement
The journal adheres to strict principles of research ethics and follows international standards (ICMJE, COPE) in determining authorship and contributor roles.
Authorship Criteria
To be listed as an author, one must have made a significant intellectual contribution to the study, including:
- Participation in research conception and design.
- Data collection, analysis, or interpretation.
- Drafting or critically revising the manuscript.
- Approval of the final version for publication.
The following do not qualify for authorship:
- Funding acquisition alone.
- Provision of materials or technical assistance only.
- General supervision without direct scientific input.
Authorship Order
- Author order should reflect relative contributions (first author = primary researcher, last author = senior supervisor).
- All authors must approve the submitted manuscript and take responsibility for its content.
- Changes to the author list after submission require written consent from all authors and editorial approval.
Author Responsibilities
Each author must:
- Disclose their specific contributions (using CRediT – Contributor Roles Taxonomy).
- Justify the inclusion of all co-authors and explain any omissions.
- Cooperate in resolving authorship disputes.
Special Cases
- Group authorship (consortia, collaborations) – must specify the group’s role and a contact person.
- Non-author contributors (e.g., statistical support) – should be acknowledged in the "Acknowledgements" section with their consent.
Disputes and Violations
- Authorship disputes will be investigated by the editorial board (drafts, correspondence, or lab records may be requested).
- Unjustified inclusion/exclusion of authors may lead to manuscript rejection or retraction.
- "Guest" or "gift" authorship (adding non-contributors) is prohibited and considered unethical.
Contribution Statement
Upon submission, authors must complete a "Contributor Roles" form (e.g., following CRediT standards), detailing:
- Conceptualization – Idea formulation; overarching research goals.
- Data Curation – Managing, annotating, and archiving research data.
- Formal Analysis – Applying statistical/mathematical/computational techniques.
- Funding Acquisition – Securing financial support for the project.
- Investigation – Conducting experiments/data collection.
- Methodology – Designing research methods and protocols.
- Project Administration – Overseeing research planning and execution.
- Resources – Providing materials, tools, or infrastructure.
- Software – Developing, programming, or testing software.
- Supervision – Leading and mentoring the research team.
- Validation – Verifying reproducibility and accuracy of results.
- Visualization – Preparing figures, diagrams, or presentations.
- Writing – Original Draft – Creating the first manuscript version.
- Writing – Review & Editing – Revising and refining the manuscript.
These roles help clarify individual contributions in multi-author papers, improving transparency in academic publishing. The journal reserves the right to request additional clarification on authorship at any stage of peer review.
This policy aligns with ICMJE (International Committee of Medical Journal Editors) and COPE (Committee on Publication Ethics) guidelines.
Complaints and Appeals Policy
The journal is committed to maintaining fairness, transparency, and objectivity in handling all complaints and appeals. This policy follows COPE (Committee on Publication Ethics) guidelines and international standards of scholarly publishing.
Types of Complaints Considered
The journal will review:
- Appeals of editorial decisions (rejection, revision requests)
- Allegations of publication ethics violations
- Concerns about peer review quality
- Conflicts between authors, reviewers, and editors
- Accusations of plagiarism or data fabrication
Submission Process
- Complaints must be sent to the Editor-in-Chief via the journal's official email: clinvest@mail.ru.
- The complaint should include:
- Manuscript ID (number) in the publication system, article title, article authors (if applicable)
- Detailed description of the issue
- Supporting evidence and materials
- Complainant's contact information
Review Procedure
Initial Assessment (3 business days):
- Acknowledgement of receipt
- Evaluation of complaint validity
Formal Investigation (15-30 business days):
- Formation of an independent review panel
- Collection of additional information
- Comprehensive case examination
Decision Making:
- Panel reaches a conclusion
- All parties receive notification
- Retraction may be initiated for serious violations
Possible Outcomes
- Reversal of publication decision
- Additional peer review
- Publication of corrections/retractions
- Article retraction
- Temporary or permanent bans for violators
Special Cases
- Anonymous complaints require substantial evidence
- Conflicts of interest must be fully disclosed
- Repeat complaints without new evidence won't be reconsidered
Complainant Rights
- Receive a written response with rationale
- Request reconsideration with new evidence
- Escalate to COPE or publisher if dissatisfied
The journal ensures confidentiality and impartiality throughout the process. Typical resolution time is 20 business days (up to 60 for complex cases).
Policy last updated: 11.04.2025.
Conflict of Interest Policy
A conflict of interest exists when professional judgment concerning primary interests (research validity) may be potentially influenced by secondary interests (financial gain, personal relationships, academic competition). Competing interests include any financial or non-financial factors that could affect the interpretation or presentation of results.
Author Responsibilities
All authors must:
- Disclose all potential conflicts of interest upon manuscript submission
- Declare all research funding sources
- Report any financial or personal relationships with organizations/individuals that could be interested in the research outcomes
- Include a conflict of interest statement in a dedicated manuscript section
Reviewer Responsibilities
Reviewers must:
- Decline to review manuscripts where conflicts exist
- Disclose any relationships with authors that might affect objectivity
- Refrain from using unpublished manuscript information for personal benefit
Editorial Responsibilities
The editorial board will:
- Evaluate declared conflicts of interest
- Determine necessary disclosure actions
- Reserve the right to reject submissions with undisclosed significant conflicts
- Ensure editorial process objectivity
Types of Conflicts
Financial:
- Research grants and funding
- Consultancy agreements
- Stock ownership or patents
- Paid lectures
Non-financial:
- Personal relationships
- Academic competition
- Intellectual biases
- Political/religious beliefs
Disclosure Procedure
All participants must complete a disclosure form including:
- All funding sources
- Financial and non-financial interests
- Any other circumstances potentially constituting conflicts
Conflict of Interest Disclosure Form
(For Authors, Reviewers, and Editors of Medical Journals)
Journal: ___________________________________________________
Manuscript Title: __________________________________________
Date of Completion: ________________________________________
Financial Interests
Please check all applicable options:
- Grants/Funding:
- Received grants from organizations related to the research topic
- Specify source: _______________________________
- Personal Payments:
- Consulting fees
- Honoraria for lectures/presentations
- Expert testimony payments
- Specify organization: _______________________________
- Stocks/Patents:
- Ownership of stocks/options in companies related to the research
- Patents (pending/issued) for technologies/drugs mentioned in the work
- Specify details: _______________________________
- Other Funding:
- Compensation for study participation
- Travel/accommodation expenses for conferences
- Other (specify): _______________________________
Non-Financial Interests
- Academic/Professional Relationships:
- Personal/family relationships with authors, reviewers, or editors
- Competing research projects
- Membership in advisory boards/associations
- Intellectual Preferences:
- Commitment to specific methodologies/theories
- Public stance on controversial issues related to the topic
- Other:
- Political/religious beliefs that may influence data interpretation
- Other (specify): _______________________________
Declaration
I, _________________________ (Full Name), confirm:
- No conflicts of interest
- The presence of conflicts of interest (listed above)
Signature: _________________________
Date: _________________________
Notes:
For pharmaceutically-funded research, additionally specify:
- Sponsor's role in study design, data collection, and result interpretation.
- Existence of publication agreements regardless of study outcomes.
The editorial office reserves the right to request supporting documentation.
Non-disclosure may result in manuscript retraction or sanctions per journal policy.
This form complies with ICMJE and COPE guidelines.
Non-Disclosure Consequences
Failure to disclose may result in:
- Manuscript rejection
- Article retraction
- Publication ban
- Notification to author's institution
Declaration Format
Each publication must contain a "Conflict of Interest" section stating either:
- The authors declare no conflicts of interest
- Detailed description of all potential conflicts
Special Cases
Pharmaceutical-funded research requires additional information:
- Sponsor's role in study design
- Access to raw data
- Publication rights
Editorial Board Policy
Editorial members with conflicts must:
- Recuse themselves from related decision-making
- Disclose interests prior to discussions
- Abstain from reviewing affected manuscripts
The journal adheres to ICMJE and COPE guidelines regarding conflicts of interest. This policy undergoes regular review and updates.
This policy applies to all editorial stages – from submission through publication and post-publication discussion. All participants in the publication process are expected to comply fully with these requirements.
Last updated: 11.04.2025.
Policy on Data Sharing and Reproducibility
This policy ensures adherence to scientific ethics standards and promotes the advancement of open science. The journal adheres to the principles of open science and strives to ensure transparency, reproducibility, and reliability of published research. This policy outlines the requirements for sharing data, code, and materials necessary for verifying and replicating results.
Data Sharing
Mandatory Data Disclosure
Authors must provide the underlying research data in one of the following formats:
- Submission to data repositories.
- Deposition in open databases (if the study involves publicly available datasets).
- Inclusion in the supplementary materials of the article (if the data volume is small).
Exceptions:
- Data containing confidential or personally identifiable information may be provided in anonymized form or upon request by the editorial board.
- In cases of restrictions (e.g., commercial confidentiality, ethical guidelines), authors must justify this in the manuscript.
Data Formats
Data should be submitted in machine-readable formats (CSV, JSON, TXT, XLSX, etc.) with clear documentation (metadata, codebook).
Reproducibility of Results
Provision of Code and Scripts
- For computational and statistical research, authors must provide source code (R, Python, MATLAB, etc.) in an open repository (GitHub, GitLab, CodeOcean).
- If proprietary software was used, the version and runtime parameters must be specified.
Methodological Description
Methods should be described in sufficient detail to allow replication of the experiment or analysis.
Reproducibility Verification
- The editorial board reserves the right to request data and code from authors to verify results.
- If results cannot be reproduced, the manuscript may be rejected or sent for revision.
Licensing and Data Citation
- Authors must select an open license (CC BY, CC0) for data and code.
- If third-party data is used, the source and terms of use must be cited.
Consequences of Non-Compliance
Failure to provide data or code without valid justification may result in:
- Rejection of the manuscript.
- Retraction of the publication (if errors or irreproducibility are identified).
Contact Information
For inquiries regarding data sharing, please contact the editorial office: clinvest@mail.ru.
Policy on Biomedical Ethical Oversight
This policy governs the ethical aspects of conducting and publishing medical research involving humans, animals, biological materials, and data, ensuring the protection of participants' rights, safety, and confidentiality, and guaranteeing protection of participants' rights, safety, and confidentiality; compliance with international and national regulations; maintenance of trust within the scientific community and society.
The journal adheres to strict principles of biomedical ethics in its publication practices, following international standards, including:
- WMA Declaration of Helsinki (October 2024);
- CIOMS Guidelines (Council for International Organizations of Medical Sciences);
- ICMJE Recommendations (International Committee of Medical Journal Editors);
- COPE Principles (Committee on Publication Ethics).
When presenting the results of experimental studies involving humans or animals, authors must explicitly state in the relevant section of the manuscript whether the procedures complied with ethical standards.
Ethical Requirements for Human Research
- All studies involving human participants must be approved by a local or national ethics committee (with approval number provided).
- For retrospective studies, confirmation of ethical compliance is required.
- Participants (or their legal representatives) must provide written informed consent (oral consent is permissible only with ethics committee approval if written consent is unattainable).
- If medical data or biological materials are used, authors must indicate whether consent was obtained for research use.
- Participant data must be anonymized (identifiable information removed).
- Compliance with Russia’s Federal Law "On Personal Data" (or equivalent legislation in the study’s country) is mandatory.
- Research involving children, pregnant women, individuals with mental disorders, or other vulnerable groups requires additional justification for their inclusion and enhanced protective measures.
Ethical Requirements for Animal Research
Experimental studies involving animals must confirm adherence to national and international regulations ensuring humane treatment, including:
- EAEU Good Laboratory Practice Rules (2016);
- Russian Ministry of Health Order No. 199n (2016);
- SanPiN 2.2.1.3218-14 (requirements for animal facilities);
- GOST 33215-2019 (laboratory animal welfare standards).
Manuscripts must include:
- The ethics committee approval number for animal research;
- Measures to minimize suffering (anesthesia, humane euthanasia methods);
- Justification for animal use (absence of alternative methods).
Authors’ Responsibilities
- Data integrity: Fabrication, falsification, or image manipulation (e.g., in histology/radiology) is prohibited.
- Conflict of interest: Authors must disclose financial ties to pharmaceutical companies, equipment manufacturers, or other stakeholders.
- Plagiarism & duplicate publication: Reusing data (own or others’) without proper citation is forbidden.
Editorial & Reviewer Responsibilities
- The editorial team verifies ethics committee approval during manuscript review.
- Reviewers must report suspected ethical violations (e.g., lack of informed consent, animal mistreatment).
- Editors may request additional documentation (ethics protocols, consent forms) if concerns arise.
Investigation of Violations
If ethical breaches are identified, the journal reserves the right to:
- Reject the manuscript at any stage;
- Retract a published article, notifying readers, repositories, and indexing databases;
- Report to the authors’ institutional ethics committee for further investigation;
- Impose a submission ban (up to 5 years) on offending authors.
Transparency & Corrections
- The journal publishes notices, corrections, and retractions if ethical violations are confirmed.
- Readers and authors may report concerns via email: clinvest@mail.ru.
Effective Date: April 11, 2025.
Policy for Post-Publication Discussions and Corrections
The journal is committed to maintaining high standards of scientific publication and ensuring transparency, error correction, and open discussion of published materials. After publication, the following options are available for interaction with authors and readers:
Corrections
- Minor errors (typos, small inaccuracies in data that do not affect conclusions) – a Corrigendum is published, specifying the changes.
- Errors introduced by the editorial team/publisher – a Publisher’s Note is issued.
- Major errors identified by authors or readers that affect the interpretation of results but do not invalidate the main conclusions – an Erratum is published with an explanation of the corrections.
Addenda
- If authors wish to provide additional significant information clarifying the study (without altering the conclusions), an Addendum may be published.
Comments & Replies
- Readers may submit a critical comment on an article, which, after peer review, will be published alongside the authors’ response.
- If the comment reveals serious concerns, the editorial board may initiate a further review of the article.
Article Retraction
An article may be retracted in cases of:
- Major errors that invalidate the conclusions.
- Ethical violations (plagiarism, data fabrication, duplicate publication).
- Unresolved conflicts of interest that were undisclosed at the time of publication.
A Retraction Notice will be issued, explaining the reasons for retraction.
Updated Versions (Versioning)
- In exceptional cases (e.g., discovery of new data), an article may be revised and republished as an updated version labeled "Revised Version".
Procedure for Initiating Changes
- Readers: May submit requests by emailing the editorial office: clinvest@mail.ru.
- Authors: Must notify the editorial team of any identified errors.
- Editors: Will make a decision after consulting reviewers and authors.
The journal reserves the right to modify this policy in accordance with COPE (Committee on Publication Ethics) guidelines and international standards of scientific publishing.
Last updated: 11.04.2025.
Policy upon detection of fraudulent publication
On Responsibility for Falsified Research (including falsification committed using Generative Artificial Intelligence)
- General Provisions and Definitions
1.1. A falsified publication is defined as a manuscript in which:
- genuine primary data from experiments, observations, surveys, or measurements are absent;
- numerical values, graphs, statistical relationships, or conclusions are artificially generated, including by means of Generative Artificial Intelligence (AI) (e.g., ChatGPT, GigaChat, YandexGPT, Midjourney, DALL-E, DeepSeek, and similar);
- fictitious sources are cited, or the content of real sources is distorted;
- a methodology is described but was not actually applied.
1.2. The use of AI as a supporting tool (editing, structuring, translation, grammar and spelling checking, hypothesis generation) shall not be considered falsification, provided that such use is explicitly disclosed in a special disclaimer — the Declaration on the Use of AI (for example: "In preparing this work, the author(s) used [NAME AND VERSION OF THE TOOL] for [RATIONALE]. After using this tool/service, the author(s) reviewed and edited the content and accept(s) full responsibility for the content of the publication").
Data analysis, code generation for processing real data, research design, literature searches in the Materials and Methods section, and the creation of illustrations, schemes, or diagrams shall be disclosed in the figure caption.
1.3. Exclusive responsibility for the accuracy and authenticity of all data lies with the author(s).
- Civil Liability (Civil Code of the Russian Federation)
Upon confirmation of falsification, the following measures based on the norms of the Civil Code of the Russian Federation shall apply to the author(s):
2.1. Protection of the Journal's Business Reputation (Article 152 of the Civil Code)
The Journal shall have the right to seek through court:
- a retraction of the false information (the falsified research) in the same manner in which it was disseminated;
- removal of the published article from the website and from databases;
- compensation for moral harm caused by the dissemination of information defaming the Journal's business reputation (the amount shall be determined by the court, but the Journal shall claim no less than 500,000 rubles).
Legal basis:
Article 152, paragraph 11 of the Civil Code: "The rules on the protection of a citizen's business reputation shall apply accordingly to the protection of the business reputation of a legal entity."
2.2. Recovery of Damages (Articles 15, 393 of the Civil Code)
The Journal shall have the right to recover from the authors in full:
- costs of peer review (actual cost — up to 30,000 rubles);
- costs of editing, typesetting, proofreading, DOI assignment (up to 50,000 rubles);
- costs of publication in the printed version (up to 20,000 rubles);
- lost profits (e.g., refusal of a publisher to continue cooperation with the Journal due to reputational damage).
Legal basis:
*Article 15 of the Civil Code: "A person whose right has been violated may demand full compensation for the losses caused to him/her."*
2.3. Invalidity of the Transaction (Articles 168, 179 of the Civil Code)
The submission of a manuscript and the conclusion of an author agreement with full falsification of data shall be deemed an invalid transaction concluded under the influence of fraud.
Consequences: bilateral restitution shall not apply; everything received by the Journal (editorial and publication fees) shall remain with the Journal, and what the author received (publication) shall be annulled.
Legal basis:
Article 179, paragraph 2 of the Civil Code: "A transaction concluded under the influence of fraud may be declared invalid by a court at the claim of the injured party. Fraud also includes intentional silence about circumstances which the person should have disclosed."
2.4. Unjust Enrichment (Article 1102 of the Civil Code)
If the author received an honorarium or other payments from the Journal for a falsified article, he/she shall be obliged to return them as unjust enrichment within 10 days of the date the claim is made.
Legal basis:
Article 1102 of the Civil Code: "A person who, without grounds established by law or by transaction, has acquired property at the expense of another person, shall be obliged to return to the latter the unjustly acquired property."
- Administrative Liability (Code of Administrative Offences of the Russian Federation)
The Journal shall have the right (and, where signs exist, the obligation) to submit materials to Roskomnadzor, the Ministry of Internal Affairs, or the Prosecutor's Office to hold the author administratively liable under the following articles:
3.1. Dissemination of False Information (Article 13.15 of the Administrative Code)
This shall apply if the falsified research concerns socially significant topics (medicine, safety, ecology) and misleads an indefinite circle of persons.
Sanction: a fine on citizens from 30,000 to 100,000 rubles; on officials — from 60,000 to 200,000 rubles; on legal entities — from 200,000 to 500,000 rubles.
3.2. Violation of the Procedure for Using AI Technologies
As of the date of this document, no special offence is provided for. However, the Journal declares that the generation of false data using AI shall be considered an aggravating circumstance under Article 4.3 of the Administrative Code (commission of an offence using technical means).
- Criminal Liability (Criminal Code of the Russian Federation)
The Journal hereby notifies that a falsified research may contain elements of crimes provided for by the following articles of the Criminal Code. If any of the signs listed below are present, the Journal shall be obliged to file a report with the Investigative Committee or the Ministry of Internal Affairs.
4.1. Fraud (Article 159 of the Criminal Code)
Conditions for application:
- The falsified research was presented to obtain a grant, subsidy, state contract, budget funding, scholarship, or prize.
- Funds or other property (including the right to publication at the expense of a grant) were transferred to the author.
Qualifying features:
- On a large scale (over 250,000 rubles) — Part 2 of Article 159 of the Criminal Code → a fine of up to 300,000 rubles, or compulsory labour for up to 3 years, or imprisonment for up to 3 years.
- On an especially large scale (over 1 million rubles) — Part 4 of Article 159 of the Criminal Code → imprisonment for up to 10 years with a fine of up to 1 million rubles.
- Committed by a group of persons pursuant to a prior conspiracy (e.g., by all co-authors) — Part 2 of Article 159 of the Criminal Code.
Legal basis:
Article 159, paragraph 1 of the Criminal Code: "Theft of another's property or acquisition of the right to another's property by fraud or abuse of trust."
4.2. Official Forgery (Article 292 of the Criminal Code)
Applies if the author is an official (employee of a state university, research institute, state body, expert of the Ministry of Education and Science) and has knowingly included false information in an official report, expert opinion, or dissertation council.
Sanction: a fine of up to 80,000 rubles, or compulsory labour for up to 480 hours, or corrective labour for up to 2 years, or arrest for up to 6 months.
4.3. Falsification of Evidence (Article 303 of the Criminal Code)
Applies if the falsified research is presented to a court as an expert opinion or scientific justification in a civil, arbitration, or criminal case.
Sanction (Part 1 of Article 303 of the Criminal Code): a fine of up to 300,000 rubles, or compulsory labour for up to 480 hours, or arrest for up to 4 months.
4.4. Copyright Infringement (Article 146 of the Criminal Code)
Applies if in the process of falsification the author has unlawfully used another person's real data (e.g., copied graphs from another article) or appropriated authorship.
Sanction (Part 2 of Article 146 of the Criminal Code): a fine of up to 200,000 rubles, or compulsory labour for up to 480 hours, or arrest for up to 6 months.
4.5. Negligence (Article 293 of the Criminal Code) — for a research supervisor or reviewer
Applies if they knew for certain about the falsification but allowed publication, and this caused major damage (to the reputation of the Journal or the state budget).
Sanction: a fine of up to 200,000 rubles, or corrective labour for up to 2 years, or imprisonment for up to 3 months (Part 1 of Article 293 of the Criminal Code).
- Special Legal Consequences
5.1. Annulment of an Academic Degree (Article 4 of Federal Law No. 127-FZ "On Science and State Scientific and Technical Policy")
The Journal shall submit a representation to the Higher Attestation Commission (VAK) under the Ministry of Education and Science of the Russian Federation for the annulment of a Candidate's or Doctor's degree diploma if the falsified research formed the basis of a dissertation.
5.2. Expulsion from an Educational Institution (Article 43 of Federal Law No. 273-FZ "On Education in the Russian Federation")
For submitting a falsified research as a term paper, graduate thesis, or Master's thesis — expulsion without the right to reinstatement for "academic dishonesty."
- Joint and Several Liability of Co-authors
6.1. All co-authors shall bear joint and several civil liability (Article 322 of the Civil Code) for losses incurred by the Journal in connection with falsification.
6.2. Each co-author, by signing the author agreement, confirms that he/she has personally reviewed the raw data and methodology. A reference to the fact that "the first author was responsible for the data" or "the data was generated by AI" shall not be accepted and shall not serve as a ground for exemption from liability (Article 322 of the Civil Code).
- Procedure for Applying Sanctions
7.1. Upon detection of signs of falsification, the Editorial Board shall establish an Ethics Committee (3 members of the Editorial Board not affiliated with the authors).
7.2. A request for raw data shall be sent to the author(s). The deadline shall be 14 calendar days. Refusal, inability to provide raw data, or provision of data manifestly generated by AI (according to the conclusion of systems such as Antiplagiat, Domate, Rukontest, Plagiat AI, or similar) shall be deemed confirmation of falsification.
7.3. The decision on retraction shall be published in the nearest issue of the Journal with the wording: "The article has been retracted due to complete falsification of data, including the use of Generative AI."
7.4. Within 30 days from the date the fact is established, the Journal shall send the materials:
- to law enforcement authorities (where signs of Articles 159, 292, 303 of the Criminal Code are present);
- to the VAK / Ministry of Education and Science (where an academic degree is held);
- to the Retraction Watch system and databases (Scopus, WoS, RSCI/РИНЦ).
- Absence of Mitigating Circumstances
The following arguments shall not constitute grounds for mitigating or setting aside liability:
- "The data was generated by a neural network without my knowledge";
- "I do not know how to verify the quality of AI-generated data";
- "AI is a new tool, and the law does not regulate it";
- "Other authors do the same."
The Journal follows the position of the Higher Attestation Commission (VAK) and the Ministry of Education and Science: concealment of the use of AI to generate false data is a form of fraud, equivalent to direct forgery.
- Final Provisions
9.1. This Policy is an integral part of the Author Agreement (paragraph 2 of Article 428 of the Civil Code) and shall be published on the Journal's website in open access.
9.2. By submitting a manuscript, the author confirms that he/she has read the Policy and agrees to its terms in full.
9.3. The Policy shall apply to manuscripts submitted after the date of its publication, as well as to already published articles if falsification is discovered at any time after publication (the statute of limitations shall not apply due to the continuing nature of the violation, Article 208 of the Civil Code).
Appendix:
Signature of each co-author confirming their awareness of the Policy and responsibility for falsification.
"I, [FULL NAME], confirm that I have read the Journal's Policy on Responsibility for Falsified Research. I am aware that complete falsification, including the use of Generative AI, entails civil liability (Articles 15, 152, 179, 1102 of the Civil Code) and potential criminal liability (Articles 159, 292, 303, 146 of the Criminal Code). I undertake to keep the primary data for at least 5 years and to provide them at the first request of the Editorial Board. I am aware that a reference to lack of knowledge of the origin of the data does not relieve me of liability."
Effective Date: 10 May 2026
Status: Integral part of the Author Agreement and of the Journal's Publication Ethics.
